Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Tipo del documento
Intervalo de año de publicación
1.
Eur J Pharm Biopharm ; 169: 12-19, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34508807

RESUMEN

In preclinical drug development, ex vivo and in vitro permeability studies are a decisive element for specifying subsequent development steps. In this context, reliability, physiological alignment and appropriate in vivo correlation are mandatory for predictivity regarding drug absorption. Especially in oromucosal drug delivery, these prerequisites are not adequately met, which hinders its progressive development and results in the continuous need for animal experiments. To address current limitations, an innovative, standardized, and controlled ex vivo permeation model was applied. It is based on Kerski diffusion cells embedded in automated sampling and coupled to mass spectrometric quantification under physiologically relevant conditions. This study aimed to evaluate the predictivity of the developed model using porcine mucosa (ex vivo) in relation to data of sublingual propranolol absorption (in vivo). In addition, the usefulness of biomimetic barriers (in vitro) as a replacement for porcine mucosa was investigated. Therefore, solubility and permeability studies considering microenvironmental conditions were conducted and achieved good predictivity (R2 = 0.997) for pH-dependent permeability. A multiple level C correlation (R2 ≥ 0.860) between obtained permeability and reported pharmacokinetic animal data (AUC, Cmax) was revealed. Furthermore, a point-to-point correlation was demonstrated for several sublingual formulations. The successful IVIVC confirms the standardized ex vivo model as a viable alternative to animal testing for estimating the in vivo absorption behavior of oromucosal pharmaceuticals.


Asunto(s)
Absorción por la Mucosa Oral/fisiología , Propranolol/farmacocinética , Administración Sublingual , Antagonistas Adrenérgicos beta/farmacocinética , Animales , Desarrollo de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/métodos , Modelos Animales , Mucosa Bucal/fisiología , Permeabilidad , Porcinos
2.
Biol Pharm Bull ; 43(10): 1448-1450, 2020 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-32759600

RESUMEN

Japanese allergic subjects are commonly sensitized to both house dust mite (HDM) and Japanese cedar pollen (JCP) and combined treatment with sublingual immunotherapy (SLIT) tablets is desirable. However, mixing extracts of two non-homologous allergens may compromise allergen stability and affect the clinical outcome. Therefore, we investigated the stability of major allergens and total allergenic reactivity of HDM and JCP SLIT-tablets following dissolution in human saliva or artificial gastric juice. Two fast-dissolving freeze-dried SLIT-tablets were completely dissolved and incubated at 37 °C. Major allergen concentrations and total allergenic reactivity were measured. After mixing and co-incubation of HDM and JCP SLIT tablets in human saliva for 10 min at 37°C, there were no statistically significant changes in major allergen concentrations. In addition, no loss of allergenic reactivity of the mixed two SLIT-tablet solutions was seen. In contrast, complete loss of allergenic reactivity and detectable major allergen concentrations occurred when the two SLIT-tablets were dissolved and incubated in artificial gastric juice. These results demonstrate that HDM or JCP major allergens and the total allergenic reactivity of both SLIT-tablets measured here remain intact after dissolution and co-incubation in human saliva, supporting the possibility of a dual HDM and JCP SLIT-tablet administration regimen if clinically indicated. The complete loss of allergenic reactivity after incubation in artificial gastric juice can furthermore be taken to indicate that the immunological activity of the allergen extracts contained in the two SLIT-tablets is likely to be lost or severely compromised upon swallowing.


Asunto(s)
Alérgenos/química , Antígenos Dermatofagoides/química , Polen/inmunología , Rinitis Alérgica/terapia , Inmunoterapia Sublingual/métodos , Administración Sublingual , Alérgenos/administración & dosificación , Alérgenos/farmacocinética , Antígenos Dermatofagoides/administración & dosificación , Cryptomeria/inmunología , Composición de Medicamentos/métodos , Liberación de Fármacos , Estabilidad de Medicamentos , Humanos , Japón , Mucosa Bucal/química , Mucosa Bucal/metabolismo , Absorción por la Mucosa Oral , Rinitis Alérgica/etiología , Saliva/química , Comprimidos , Resultado del Tratamiento
3.
Int J Pharm ; 584: 119411, 2020 Jun 30.
Artículo en Inglés | MEDLINE | ID: mdl-32423876

RESUMEN

The aim of this study was to formulate an easily-administered, safe and effective dosage form loaded with meclizine for treatment of chemotherapy-induced nausea and vomiting (CINV) through the buccal route. CINV comprises bothersome side effects accompanying cytotoxic drugs administration in cancer patients. Meclizine was loaded in chitosan-pectin nanoparticles which were further incorporated within a buccal film. Different formulations were prepared based on a 21.31 full factorial study using Design Expert®8. The optimum formulation possessed favorable characters regarding its particle size (129 nm), entrapment efficiency (90%) and release profile. Moreover, its permeation efficiency through sheep buccal mucosa was assessed via Franz cell diffusion and confocal laser microscopy methods. Enhanced permeation was achieved compared with the free drug form. In-vivo performance was assessed using cyclophosphamide induced emesis. The proposed formulation exerted significant relief of the measured responses (reduced body weight and motor coordination, elevated emesis, anorexia, proinflammatory mediators and neurotransmitters that were also associated with scattered degenerated neurons and glial cells). The developed formulation ameliorated all behavioral, biochemical and histopathological changes induced by cyclophosphamide. The obtained data were promising suggesting that our bioadhesive formulation can offer an auspicious medication for treating distressing symptoms associated with chemotherapy for cancer patients.


Asunto(s)
Antieméticos/farmacología , Quitosano/química , Meclizina/farmacología , Nanopartículas/química , Pectinas/química , Vómitos/tratamiento farmacológico , Administración Bucal , Animales , Antieméticos/administración & dosificación , Antieméticos/farmacocinética , Antineoplásicos/efectos adversos , Química Farmacéutica/métodos , Ciclofosfamida/efectos adversos , Citocinas/biosíntesis , Preparaciones de Acción Retardada , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/farmacología , Liberación de Fármacos , Humanos , Concentración de Iones de Hidrógeno , Mediadores de Inflamación/metabolismo , Masculino , Meclizina/administración & dosificación , Meclizina/farmacocinética , Microscopía Electrónica de Transmisión , Neurotransmisores/metabolismo , Absorción por la Mucosa Oral/fisiología , Ratas , Ratas Wistar , Ovinos , Espectroscopía Infrarroja por Transformada de Fourier , Resistencia a la Tracción , Vómitos/inducido químicamente
4.
Eur J Pharm Sci ; 130: 215-224, 2019 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-30716381

RESUMEN

The present report demonstrates a quality by design approach to understand and optimize self-nanoemulsifying orodispersible films (SNEODF) of captopril for hypertension. A central composite experimental design was used to study the formulation parameters effects (primary emulsion, aqueous phase, and surfactant) on the film properties (globule size, film burst, adhesion, Young's moduli, disintegration time, tensile strength and dissolution). Principle component analysis (PCA) and principle component regression (PCR) were employed to identify and quantify the effects of formulation variables and physico-mechanical properties of the film on the drug permeability. PCA classified three distinct groups of film formulations based on their composition and properties. PCR quantified the impact of main variables, their interactions, and square effects on the drug permeability. The main effect of the aqueous phase exhibited a negative impact, while that of flux and tensile strength showed a positive impact on the permeability. Interactions of primary emulsions with disintegration time and tensile strength displayed a synergistic impact. Interactions of aqueous phase with flux, Young's moduli, and tensile strength, as well as between Young's moduli and tensile strength showed a significant positive effect on the permeability. A negative correlation of square effects of primary emulsion and flux, and a positive square effect of Young's moduli confirmed their non-linear influence on the drug permeability across porcine buccal mucosa. This research work demonstrates application of design of experiment and multivariate methods to achieve targeted product quality of captopril (SNEODF) having improved permeability and pH independent release profile.


Asunto(s)
Captopril/farmacocinética , Sistemas de Liberación de Medicamentos/métodos , Emulsionantes/farmacocinética , Mucosa Bucal/efectos de los fármacos , Absorción por la Mucosa Oral/efectos de los fármacos , Administración Oral , Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Inhibidores de la Enzima Convertidora de Angiotensina/farmacocinética , Animales , Captopril/administración & dosificación , Evaluación Preclínica de Medicamentos/métodos , Emulsionantes/administración & dosificación , Mucosa Bucal/metabolismo , Análisis Multivariante , Absorción por la Mucosa Oral/fisiología , Porcinos
5.
Crit Rev Food Sci Nutr ; 59(6): 982-991, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30595029

RESUMEN

Anthocyanins are natural water-soluble polyphenols present in fruits and vegetables. Health-promoting effects attributed to anthocyanins are mainly associated with oxidative stress inhibition and gut microbiota modulation. Dietary anthocyanins undergo a complex metabolism after ingestion and interact with endogenous and microbial enzymes, leading to the production of a large number of circulating and excreted anthocyanin metabolites and catabolic products. To date, the bioavailability and health benefits of anthocyanins have been widely documented. Although there are several papers that illustrated the metabolism of anthocyanins, the effects of dietary anthocyanins on the modulation of the gut microbial ecology and on the growth of certain microbial species are still poorly understood. The present paper summarizes the recent data on the absorption of anthocyanins in the upper gastrointestine and the metabolism of anthocyanins by gut microbiota. The modulatory effects of anthocyanins from different sources on gut microbiota are also discussed.


Asunto(s)
Antocianinas/metabolismo , Antocianinas/farmacocinética , Microbioma Gastrointestinal/efectos de los fármacos , Microbioma Gastrointestinal/fisiología , Disponibilidad Biológica , Dieta , Suplementos Dietéticos , Frutas/química , Absorción Gástrica , Humanos , Beneficios del Seguro , Absorción Intestinal , Absorción por la Mucosa Oral , Estrés Oxidativo/efectos de los fármacos , Polifenoles , Verduras/química
6.
Eur J Drug Metab Pharmacokinet ; 44(2): 169-177, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30328058

RESUMEN

BACKGROUND AND OBJECTIVES: The importance of quercetin and flavonoids in the diet and as food supplements is well known, and literature studies support their potential use to treat several human diseases. Many beneficial properties have been described for quercetin, so much effort has been directed into overcoming the major drawbacks of this natural compound-its poor solubility and low oral absorption. The aims of this study were to compare a new food-grade lecithin-based formulation of quercetin, Quercetin Phytosome®, to unformulated quercetin in terms of solubility in simulated gastrointestinal fluids and oral absorption in a randomized crossover pharmacokinetic study of healthy volunteers. METHODS: The solubility of the new formulation was determined by in vitro incubation in simulated gastrointestinal fluids, and quercetin was detected by ultra performance liquid chromatography. A single-dose, randomized, six-sequence/three-period crossover clinical trial (3 × 3 × 3 crossover design) with a balanced carryover effect was conducted in healthy volunteers under fasting conditions. Twelve healthy volunteers of both sexes with an age range of 18-50 years were recruited; one dose of quercetin and two different doses of Quercetin Phytosome were administered orally as film-coated tablets. Pharmacokinetic samples were collected at twelve time points (from 0 h to 24 h) after administration, and quercetin levels were measured by HPLC/MS/MS. Data were analyzed using the Phoenix WinNonlin (v.6.4) software package, and the most significant pharmacokinetic parameters were calculated. Statistical analysis involved performing a two-way ANOVA with repeated measures followed by post hoc analysis (Tukey's test). RESULTS: Significant improvements in both in vitro solubility and oral absorption (in terms of both exposure and maximum concentration achieved) by healthy volunteers in a human clinical study were obtained with the Quercetin Phytosome formulation as compared to unformulated quercetin. CONCLUSIONS: A more soluble formulation of quercetin based on lecithin, Quercetin Phytosome, has recently been developed, and was found to facilitate the attainment of very high plasma levels of quercetin-up to 20 times more than usually obtained following a dose of quercetin-when the novel formulation was administered orally in human volunteers, and it did not have any notable side effects. These results suggest that Quercetin Phytosome allows the oral administration of quercetin in a safe and bioavailable manner, thus facilitating the effective utilization of this natural compound to treat various human diseases.


Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Lecitinas/administración & dosificación , Lecitinas/metabolismo , Absorción por la Mucosa Oral/efectos de los fármacos , Quercetina/administración & dosificación , Quercetina/metabolismo , Administración Oral , Adolescente , Adulto , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Ayuno/metabolismo , Femenino , Humanos , Liposomas , Masculino , Persona de Mediana Edad , Absorción por la Mucosa Oral/fisiología , Adulto Joven
7.
Nutrients ; 10(3)2018 03 12.
Artículo en Inglés | MEDLINE | ID: mdl-29534507

RESUMEN

We investigated if a carbohydrate (CHO) mouth rinse may attenuate global fatigue and improve 4-km cycling time trial (TT4km) performance. After a preliminary session, cyclists (n = 9) performed a TT4km after a CHO or placebo (PLA) mouth rinse. Mean power output, time, and ratings of perceived exertion (RPE) were recorded throughout the TT4km. Twitch interpolation responses (%VA; voluntary activation and ∆Tw; delta peak twitch torque) were compared pre and post TT4km with traditional statistics and effect size (ES) analysis. Time-to-complete the 4 km and mean power output were comparable between CHO (386.4 ± 28.0 s) and PLA (385.4 ± 22.4 s). A lower central (p = 0.054) and peripheral (p = 0.02) fatigue in CHO than in PLA were suggested by an extremely-large ES in %VA (manipulation main effect: p = 0.052, d = 1.18; manipulation-by-time interaction effect: p = 0.08, d = 1.00) and an extremely, very-large ES in ∆Tw (manipulation main effect: p = 0.07, d = 0.97; time-by-manipulation interaction effect: p = 0.09, d = 0.89). The RPE increased slower in CHO than in PLA (p = 0.051; d = 0.7). The apparent reduction in global fatigue (central and peripheral) and RPESLOPE with only one CHO mouth rinse were not translated into improved TT4km performance. Further tests may be required to verify if these likely differences in global fatigue might represent an edge in the short-lasting cycling time trial performance.


Asunto(s)
Rendimiento Atlético , Ciclismo , Carbohidratos de la Dieta/administración & dosificación , Fatiga/prevención & control , Antisépticos Bucales/administración & dosificación , Sustancias para Mejorar el Rendimiento/administración & dosificación , Administración a través de la Mucosa , Adulto , Brasil , Carbohidratos de la Dieta/metabolismo , Carbohidratos de la Dieta/uso terapéutico , Suplementos Dietéticos , Método Doble Ciego , Fatiga/etiología , Fatiga/metabolismo , Humanos , Masculino , Antisépticos Bucales/metabolismo , Antisépticos Bucales/uso terapéutico , Fatiga Muscular , Absorción por la Mucosa Oral , Consumo de Oxígeno , Sustancias para Mejorar el Rendimiento/metabolismo , Sustancias para Mejorar el Rendimiento/uso terapéutico , Esfuerzo Físico , Recreación , Fenómenos Fisiológicos en la Nutrición Deportiva , Factores de Tiempo
8.
Int J Pharm ; 535(1-2): 164-171, 2018 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-29107614

RESUMEN

Hydroxysafflor yellow A (HSYA) is the main bioactive flavonoid extracted from the flower of Carthamus tinctorius L., which is widely used in traditional Chinese medicine for the treatment of myocardial ischemia and cerebral ischemia. HSYA has high water solubility but poor intestinal membrane permeability, resulting in low oral bioavailability. Currently, only HSYA sodium chloride injection has been approved for clinical use and oral formulations are urgently needed. In this study, HSYA solid lipid nanoparticles (SLNs) with the structure of w/o/w were prepared by a warm microemulsion process using approved drug excipients for oral delivery to increase the oral absorption of HSYA. The optimized HSYA SLNs are spherical with an average size of 214nm and the encapsulation efficiency is 55%. HSYA SLNs exhibited little cytotoxicity in Caco-2 and Hela cells, but increased the oral absorption of HSYA about 3.97-fold in rats, compared to HSYA water solution. In addition, cycloheximide pretreatment significantly decreased the oral absorption of HSYA delivered by SLNs. Importantly, the pharmacodynamics evaluation demonstrated that SLNs further decreased the infarct areas in rats. In conclude, SLNs could be a promising delivery system to enhance the oral absorption and pharmacological activities of HSYA.


Asunto(s)
Chalcona/análogos & derivados , Portadores de Fármacos/química , Flavonoides/administración & dosificación , Lípidos/química , Nanopartículas/química , Quinonas/administración & dosificación , Administración Oral , Animales , Isquemia Encefálica/tratamiento farmacológico , Células CACO-2 , Supervivencia Celular/efectos de los fármacos , Chalcona/administración & dosificación , Chalcona/farmacología , Chalcona/uso terapéutico , Liberación de Fármacos , Flavonoides/farmacología , Flavonoides/uso terapéutico , Células HeLa , Humanos , Masculino , Medicina Tradicional China , Absorción por la Mucosa Oral , Quinonas/farmacología , Quinonas/uso terapéutico , Ratas Sprague-Dawley
9.
Drugs R D ; 17(4): 615-621, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29058303

RESUMEN

BACKGROUND AND OBJECTIVE: The aim of this study was to test the hypothesis that tincture of benzoin (TOB) facilitates immediate transmucosal nicotine absorption while simultaneously promoting a safe and sustained delivery of the nicotine. METHODS: In combination with TOB, nicotine toxicity and diffusion across human mucosal cells were measured using a 3-D human mucosal tissue model. RESULTS: Nicotine was delivered 2.1 times more quickly in combination with TOB than in combination with saline (p < 0.05). Despite the increased diffusion, nicotine in combination with TOB significantly increased mucosal cell survival (p < 0.05) by reducing the release of mitochondrial cytochrome c into the cytoplasm when compared with nicotine without TOB. The average percentage distribution of cytochrome c in the cytosolic fraction over time of nicotine + 79% ethyl alcohol (ETOH) versus nicotine plus TOB (79% ETOH) was significantly different over 120 min (60.0 ± 29.9% cytosol, 16.1 ± 9.4% cytosol, p = 0.03). Related to the reduction of cytochrome c release into the cytoplasm, TOB suppressed caspase-3 and -9 activity, thereby preventing intrinsic apoptosis and providing cytoprotection of the mucosal cells (ETOH + nicotine vs ETOH + nicotine + TOB: p = 0.008 for caspase 3, p < 0.001 for caspase 9). CONCLUSION: Two hours of TOB (17-24% benzoin, 79% ETOH) plus nicotine promotes diffusion of nicotine across human mucosal cells and simultaneously prevents human mucosal cell toxicity by inhibiting cytochrome c release into the cytosol, thereby preventing caspase 3 and 9 activity and subsequent intrinsic apoptosis.


Asunto(s)
Apoptosis/efectos de los fármacos , Mucosa Bucal/metabolismo , Chicles de Nicotina , Nicotina/administración & dosificación , Extractos Vegetales/administración & dosificación , Administración a través de la Mucosa , Caspasa 3/metabolismo , Caspasa 9/metabolismo , Células Cultivadas , Citocromos c/metabolismo , Difusión , Humanos , Modelos Biológicos , Mucosa Bucal/efectos de los fármacos , Nicotina/farmacocinética , Nicotina/toxicidad , Absorción por la Mucosa Oral , Extractos Vegetales/farmacocinética , Extractos Vegetales/toxicidad , Styrax/toxicidad , Supervivencia Tisular/efectos de los fármacos
10.
Planta Med ; 83(5): 461-467, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27280934

RESUMEN

The use of curcumin and resveratrol in combination has now become increasingly of interest because of their synergistic effects as therapeutic agents for various diseases, especially cancer. To overcome the poor oral bioavailability of both compounds and improve patient compliance, a novel self-microemulsifying formulation containing curcumin together with resveratrol was developed. Capryol 90, Cremophor EL, and Labrasol were selected as the oil, surfactant, and co-surfactant in the formulation, respectively, based on the solubility study of both compounds. More than 70 % and 80 % of curcumin and resveratrol, respectively, were released in 20 min. The formulation formed a fine oil in water microemulsion with droplet sizes in aqueous media of 15-20 nm. In addition, the formulation containing curcumin and resveratrol showed greater antioxidant activity than that of the formulations with individual compounds, while the cytotoxic activity against HT-29 of the co-formulation (IC50 = 18.25 µM; curcumin and resveratrol in the ratio 1 : 1) was less than the formulation with only curcumin (IC50 = 30.1 µM) and only resveratrol (IC50 = 25.4 µM). After oral administration to rabbits, the self-microemulsifying formulation containing curcumin together with resveratrol increased the total plasma concentrations of curcumin and resveratrol by 10-fold and 6-fold, respectively, compared to the unformulated combination. This study clearly demonstrated the potential use of the self-microemulsifying formulation for co-delivery, and enhanced oral absorption of poorly water-soluble natural compounds. In addition, the combination was found to produce synergistic antioxidant activity and cytotoxicity against HT-29 cells.


Asunto(s)
Antineoplásicos Fitogénicos/administración & dosificación , Antioxidantes/administración & dosificación , Curcumina/administración & dosificación , Estilbenos/administración & dosificación , Administración Oral , Animales , Antineoplásicos Fitogénicos/farmacología , Antioxidantes/farmacología , Cápsulas , Curcumina/farmacología , Sistemas de Liberación de Medicamentos , Emulsiones , Células HT29 , Humanos , Absorción por la Mucosa Oral , Vehículos Farmacéuticos , Conejos , Resveratrol , Solubilidad , Estilbenos/farmacología
11.
Oral Maxillofac Surg ; 20(3): 259-64, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27283723

RESUMEN

PURPOSE: To determine systemic absorption of dexamethasone by detection of plasma concentration using high performance liquid chromatography following its administration along with local anesthetic agent as a mixture via pterygomandibular space. METHODS: A prospective randomized double-blind clinical study was undertaken to analyze the plasma concentration of dexamethasone after intra-space pterygomandibular injection along with local anesthesia. The study was performed as per split mouth model where the mandibular quadrant allocation was done on a random basis considering each of the 30 patients is included in the two study interventions (SS and CS). For the study site (SS) procedures, dexamethasone was administered as a mixture (2 % lignocaine with 1:200,000 epinephrine and 4 mg dexamethasone) intra-space. In the control site (CS) procedures, a regular standard inferior alveolar nerve block was administered, and dexamethasone was given as intramuscular injection. The plasma dexamethasone determination was done in venous blood 30- and 60-min post injection using high performance liquid chromatography (HPLC). The clinical parameters like pain; swelling; and mouth opening on the first, third, and seventh post-operative day were analyzed and compared. RESULTS: No significant difference was found in the clinical parameters assessed; comparative evaluation showed less swelling in the SS interventions. The plasma concentration of dexamethasone for the CS interventions was 226 ± 47 ng/ml at 30-min and 316 ± 81.6 ng/ml at 60-min post injection, and for SS, it was 221 ± 81.6 ng/ml at 30-min and 340 ± 105 ng/ml at 60-min post injection. On inter-site (CS and SS) comparison, no statistically significant difference was ascertained in dexamethasone plasma concentration at 30-min post injection (P = 0.77) and at 60-min post injection. (P = 0.32). CONCLUSION: Intra-space (pterygomandibular space) administration of dexamethasone can achieve statistically similar plasma concentration of the drug as when the same dose is administered intramuscularly with demonstration of similar clinical effects.


Asunto(s)
Anestesia Dental , Anestesia Local , Cromatografía Líquida de Alta Presión/métodos , Dexametasona/administración & dosificación , Dexametasona/farmacocinética , Epinefrina/administración & dosificación , Lidocaína/administración & dosificación , Tercer Molar/cirugía , Absorción por la Mucosa Oral , Extracción Dental , Adulto , Método Doble Ciego , Combinación de Medicamentos , Femenino , Humanos , Inyecciones , Masculino , Mandíbula/efectos de los fármacos , Estudios Prospectivos , Escala Visual Analógica
12.
Artículo en Inglés | WPRIM | ID: wpr-162231

RESUMEN

OBJECTIVES: Banha-sasim-tang (BST), which consists of seven different herbs, is one of the most popular herbal formulae for treating gastrointestinal disorders in Eastern Asia. The commonly used herbal medicine is often co-administered with other therapeutic drugs, which raises the possibility of herb–drug interactions and may modify the clinical safety profile of therapeutic drugs. METHODS: We investigated the potential herb–drug interactions between BST extract and midazolam (MDZ) in mice. The area under the plasma concentration-time curve (AUC) of MDZ and 1ʹ-hydroxymidazolam (1ʹ-OH-MDZ) was evaluated for both oral and intraperitoneal administration of MDZ, following oral administration of BST (0.5 and 1 g/kg). RESULTS: It was found that the AUC of MDZ and 1ʹ-OH-MDZ was lower in case of oral administration of MDZ. Administration of BST extract was not associated with hepatic cytochrome P450 activity. BST extract induced a strong reduction in pH and it has been reported that oral mucosal absorption of MDZ is lower at low pH. The decreased absorption rate of MDZ might be caused by the ingredients of BST and may not be related to other factors such as increased excretion of MDZ by P-glycoprotein. CONCLUSIONS: The altered pharmacokinetics of midazolam caused by co-administration with BST in vivo could be attributed to a decrease in pH and subsequent reduction of MDZ absorption rate.


Asunto(s)
Animales , Ratones , Absorción , Administración Oral , Área Bajo la Curva , Sistema Enzimático del Citocromo P-450 , Asia Oriental , Interacciones de Hierba-Droga , Medicina de Hierbas , Concentración de Iones de Hidrógeno , Midazolam , Absorción por la Mucosa Oral , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP , Farmacocinética , Plasma , Estómago
14.
J Microencapsul ; 32(2): 175-80, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25413271

RESUMEN

The aim of this study was to improve the oral absorption of loratadine, a pH-sensitive drug, by self-microemulsifying drug delivery systems (SMEDDSs). The optimal SMEDDS was analysed and evaluated after emulsification in distilled water with diameter of 26.57 ± 0.71 nm and zeta potential of -30.5 ± 4.5 mV. Dissolution experiments in vitro were carried out in different released media of pH values and the SMEDDS formulations were able to release loratadine completely in different media while market tablets just performed similarly in the media of pH 1.2. Furthermore, the oral bioavailability and the pharmacokinetic behaviour of loratadine formulations in vivo were studied after a single dose of 1 mg/kg loratadine in beagle dogs. The SMEDDS formulations displayed higher Cmax and AUC, approximately 9 and 5 times increase than those of market tablets (p < 0.01) respectively. These results demonstrated that SMEDDS formulations had significantly increased the oral absorption of loratadine in beagle dogs.


Asunto(s)
Antialérgicos , Sistemas de Liberación de Medicamentos/métodos , Liberación de Fármacos , Loratadina , Absorción por la Mucosa Oral , Animales , Antialérgicos/química , Antialérgicos/farmacocinética , Antialérgicos/farmacología , Perros , Evaluación Preclínica de Medicamentos , Emulsiones , Concentración de Iones de Hidrógeno , Loratadina/química , Loratadina/farmacocinética , Loratadina/farmacología , Masculino
15.
J Pharm Sci ; 104(1): 135-43, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25417837

RESUMEN

This study investigated the oral absorption of drugs in minipigs to predict food effects in man. The protocol was based on a previously described model in dogs and further investigated the food source (i.e., US FDA breakfast or a nutritional drink) and food quantities. Two poorly soluble compounds were investigated [pravastatin (negative food effect) and atazanavir (positive food effect)] in Göttingen minipigs after seven different food regimens. The gastric emptying rate was evaluated by coadministration of acetaminophen. In short, the results demonstrated longer gastric emptying times in minipigs when compared with humans, within a range from 2.3 to 8.4 h dependent on the food regimen. There were no significant differences in drug absorption between fed and fasted state for the two compounds. The study showed that the dog protocol could not be transferred directly to minipigs, but needs further investigation and adjustments in order to get a valid model using Göttingen minipigs for the evaluation of food effects on drug absorption in humans.


Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Drogas en Investigación/farmacocinética , Interacciones Alimento-Droga , Modelos Animales , Absorción por la Mucosa Oral , Porcinos Enanos/fisiología , Administración Oral , Animales , Animales Endogámicos , Bebidas , Desayuno , Dinamarca , Perros , Drogas en Investigación/administración & dosificación , Drogas en Investigación/química , Ingestión de Energía , Vaciamiento Gástrico/efectos de los fármacos , Humanos , Masculino , Solubilidad , Especificidad de la Especie , Porcinos
16.
PLoS One ; 9(12): e115115, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25514140

RESUMEN

Given the established role of Chlamydia spp. as causative agents of both acute and chronic diseases, search for new antimicrobial agents against these intracellular bacteria is required to promote human health. Isoflavones are naturally occurring phytoestrogens, antioxidants and efflux pump inhibitors, but their therapeutic use is limited by poor water-solubility and intense first-pass metabolism. Here, we report on effects of isoflavones against C. pneumoniae and C. trachomatis and describe buccal permeability and initial formulation development for biochanin A. Biochanin A was the most potent Chlamydia growth inhibitor among the studied isoflavones, with an IC50 = 12 µM on C. pneumoniae inclusion counts and 6.5 µM on infectious progeny production, both determined by immunofluorescent staining of infected epithelial cell cultures. Encouraged by the permeation of biochanin A across porcine buccal mucosa without detectable metabolism, oromucosal film formulations were designed and prepared by a solvent casting method. The film formulations showed improved dissolution rate of biochanin A compared to powder or a physical mixture, presumably due to the solubilizing effect of hydrophilic additives and presence of biochanin A in amorphous state. In summary, biochanin A is a potent inhibitor of Chlamydia spp., and the in vitro dissolution results support the use of a buccal formulation to potentially improve its bioavailability in antichlamydial or other pharmaceutical applications.


Asunto(s)
Infecciones por Chlamydia/tratamiento farmacológico , Chlamydia trachomatis/crecimiento & desarrollo , Chlamydophila pneumoniae/crecimiento & desarrollo , Genisteína/uso terapéutico , Absorción por la Mucosa Oral/fisiología , Administración Bucal , Animales , Antibacterianos/uso terapéutico , Células Cultivadas , Chlamydia trachomatis/efectos de los fármacos , Chlamydophila pneumoniae/efectos de los fármacos , Humanos , Isoflavonas/uso terapéutico , Pruebas de Sensibilidad Microbiana , Extractos Vegetales/uso terapéutico , Porcinos
17.
Curr Drug Deliv ; 11(3): 415-25, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24295296

RESUMEN

Oral mucositis is one of the major side effects of cancer chemotherapy (30-76%) and radiotherapy (over 50%). Current palliative treatments of oral mucositis include specialized agents like pelifermin, platelet derived factors etc. or oral hygienic agents which suffered from various drawbacks like systemic side effect, least effect owing to fast wash out of buccal mucosa, patient unfriendly delivery systems, and mere symptomatic relief. In this research work, N-succinyl chitosan gel delivery system of microemulsified eugenol, honey and sodium hyaluronate was prepared to explore their multiple and synergistic effects on various pathological factors of oral mucositis. N-succinyl chitosan was synthesized in our laboratory and loaded with microemulsified eugenol (10% v/v), honey (10% v/v) and sodium hyaluronate (0.2% w/v) to prepare orogel with optimum pH, spreadability, mucoadhesion strength, and viscosity. In vitro eugenol release from N-succinyl chitosan gel after 8 hours in PBS (pH-6.4) was found to be 87.45±0.14%, which was better in comparison to that released from chitosan gel. Ex vivo penetration studies using rat buccal mucosal tissue also suggested better J-efflux of eugenol through N-succinyl chitosan in comparison to chitosan gel with enhancement ratio (ER) of 1.71. The antimicrobial effect of N-succinyl chitosan based orogel against S. aureus and C. albicans efficacy was found to be statistically high in comparison to chitosan based orogel as well as marketed formulation of chlorhexidine (p<0.05). The N-succinyl chitosan orogel in 5-fluoro uracil induced oral mucositis animal (Wistar rats) model showed enhanced survival ratio, weight gain and high tissue regeneration activity than chitosan gel formulation within 15 days. The formulation was successful in elevating the survival and reducing the inflammation in the oral mucosa of animals compared to disease control (p<0.05) and hence suggesting the potential of N-succinyl chitosan orogel in the treatment of oral mucositis.


Asunto(s)
Quitosano/química , Sistemas de Liberación de Medicamentos , Eugenol/química , Miel , Ácido Hialurónico/química , Mucosa Bucal/metabolismo , Animales , Quitosano/administración & dosificación , Eugenol/administración & dosificación , Geles , Ácido Hialurónico/administración & dosificación , Técnicas In Vitro , Absorción por la Mucosa Oral , Ratas Wistar , Estomatitis/tratamiento farmacológico , Porcinos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA